Lateef Investment Management Lowers stake in Hologic (HOLX)

Hologic (HOLX) : Lateef Investment Management reduced its stake in Hologic by 7.86% during the most recent quarter end. The investment management company now holds a total of 5,384,915 shares of Hologic which is valued at $181.7 Million after selling 459,432 shares in Hologic , the firm said in a disclosure report filed with the SEC on May 13, 2016.Hologic makes up approximately 5.73% of Lateef Investment Management’s portfolio.

Other Hedge Funds, Including , Pacer Advisors boosted its stake in HOLX in the latest quarter, The investment management firm added 563 additional shares and now holds a total of 4,076 shares of Hologic which is valued at $137,565. Hologic makes up approx 0.03% of Pacer Advisors’s portfolio. Domini Social Investments sold out all of its stake in HOLX during the most recent quarter. The investment firm sold 5,520 shares of HOLX which is valued $186,300.Great Lakes Advisors reduced its stake in HOLX by selling 8,762 shares or 6.28% in the most recent quarter. The Hedge Fund company now holds 130,663 shares of HOLX which is valued at $4.4 Million. Hologic makes up approx 0.12% of Great Lakes Advisors’s portfolio.California Public Employees Retirement System reduced its stake in HOLX by selling 3,600 shares or 0.5% in the most recent quarter. The Hedge Fund company now holds 716,300 shares of HOLX which is valued at $24.2 Million. Hologic makes up approx 0.04% of California Public Employees Retirement System’s portfolio. Renaissance Group added HOLX to its portfolio by purchasing 831,290 company shares during the most recent quarter which is valued at $28 Million. Hologic makes up approx 1.16% of Renaissance Group’s portfolio.

Hologic opened for trading at $33.57 and hit $33.8 on the upside on Wednesday, eventually ending the session at $33.61, with a gain of 0.48% or 0.16 points. The heightened volatility saw the trading volume jump to 35,33,214 shares. Company has a market cap of $9,371 M.

On the company’s financial health, Hologic reported $0.47 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.46. The company had revenue of $693.30 million for the quarter, compared to analysts expectations of $687.43 million. The company’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.41 EPS.

Many Wall Street Analysts have commented on Hologic. Hologic was Downgraded by Needham to ” Hold” on Apr 28, 2016.

Hologic Inc. is a developer manufacturer and supplier of diagnostics products medical imaging systems and surgical products. The Company’s business units are focused on diagnostics breast health GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays its ThinPrep system the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases chlamydia and gonorrhea certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems an ultrasound-based osteoporosis assessment product and its Fluoroscan mini C-arm imaging products.

Leave a Reply

Hologic - Is it time to Sell?

Top Brokerage Firms are advising their investors on Hologic. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.